Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical ...
PHILADELPHIA, June 17, 2025 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) reported long-term clinical outcomes for the largest single center cohort of individuals who ...
CORPUS CHRISTI, Texas (KTRK) -- A Corpus Christi family is going through a big battle. Soon, the mother will be traveling to Houston to give birth to her son who, right now, only has half his heart.
CORPUS CHRISTI — According to the March of Dimes, 1 in 100 babies is born with a heart defect in the U.S. each year. One family affected by a critical form of a Congenital Heart Defect is the Rivera’s ...
MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (LGVN) (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term ...
New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per year MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- ...
HOUSTON, Texas (KTRK) -- A Corpus Christi baby born with half of a heart here in Houston has passed away. ABC13 first told you about Alexis Rivera, who moved to Houston temporarily to have her baby at ...
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback